Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and Cyclophosphamide
Authors: Fadi Fakhouri, Luis Teixeira, Richard Delarue, Jean-Pierre Grünfeld, Agnès Veyradier
Journal: Annals of Internal Medicine (2004)

Letters17 February 2004Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and CyclophosphamideFadi Fakhouri, MD, Luis Teixeira, MD, Richard Delarue, MD, Jean-Pierre Grünfeld, MD, and Agnès Veyradier, MD, PhDFadi Fakhouri, MDFrom Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France., Luis Teixeira, MDFrom Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France., Richard Delarue, MDFrom Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France., Jean-Pierre Grünfeld, MDFrom Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France., and Agnès Veyradier, MD, PhDFrom Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-4-200402170-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We agree with Zheng and colleagues (1) that rituximab is a promising alternative to all other immunosuppressive treatments in chronic relapsing thrombotic thrombocytopenic purpura due to an acquired deficiency in a von Willebrand factor–cleaving protease (vWF-cp), ADAMTS13. However, data regarding the use of rituximab as a single agent in thrombotic thrombocytopenic purpura are particularly scarce. We report our experience with rituximab as monotherapy in a patient with relapsing thrombotic thrombocytopenic purpura due to an anti-ADAMTS13 antibody.A 38-year-old man had a 24-year history of relapsing thrombotic thrombocytopenic purpura. Between 1978 and 2001, he had 13 relapses requiring ...Reference1. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105-8. [PMID: 12529092] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hôpital Necker, 75015 Paris, France; and Hôpital Antoine-Béclère, 92140 Clamart, France. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRemission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab Xinglong Zheng , Arnel M. Pallera , Lawrence T. Goodnough , J. Evan Sadler , and Morey A. Blinder Correction: Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and Cyclophosphamide Metrics Cited ByExpert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraThrombotic Microangiopathy, Cancer, and Cancer DrugsGain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpuraNovel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpuraRituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case reportNew treatment options for immune-mediated hematological disordersRituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literatureTargeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpuraRemission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disordersImmunotherapy for thrombotic thrombocytopenic purpuraSplenectomy for the treatment of thrombotic thrombocytopenic purpuraCardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximabRituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case reportÉvolution des indications et de la consommation du plasma frais congelé de 1997 à 2003 dans un hôpital universitaireWhy Do We Need ADAMTS13?Correction: Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and Cyclophosphamide 17 February 2004Volume 140, Issue 4Page: 314-315KeywordsAntibody therapyBlood plasmaCyclophosphamideImmunosuppressivesIntravenous immunoglobulinProteasesSplenectomySteroidsThrombotic thrombocytopenic purpuraVentilators ePublished: 17 February 2004 Issue Published: 17 February 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...